Breast cancer patients with positive expression of estrogen receptor (ER) or progesterone receptor (PgR) without expression of HER2 receptor are good candidates for endocrine therapy with fewer toxicities but equivalent treatment outcomes to chemotherapy. Here, PGR is linked to breast carcinoma.